🎉 Pharmidex Celebrates Scientific Achievement! 🧪

January 27, 2025

We are thrilled to announce that members of the Pharmidex team have contributed to groundbreaking research, published in the prestigious journal International Journal of Molecular Sciences

📄 The paper, titled "Biomass-Derived Nanoporous Carbon Honeycomb Monoliths for Environmental Lipopolysaccharide Adsorption from Aqueous Media", explores innovative solutions for environmental challenges using advanced materials science.

👏 We extend our heartfelt congratulations and gratitude to all the authors for their dedication and hard work in bringing this important research to life.

🔗 Curious about the study? You can read the full article here: Read the Article (https://www.mdpi.com/1422-0067/26/3/952#)

We are proud to support and celebrate cutting-edge science that drives meaningful impact. Let’s continue pushing the boundaries of innovation! 🚀

#Pharmidex #Research #Innovation #Nanotechnology #Sustainability #Science

< Older Post

Newer Post >

Congratulate Ash Alavijeh as Chief Operating Officer

May 7, 2026

We are delighted to announce and congratulate Ash Alavijeh on his appointment as Chief Operating Officer at Pharmidex . Ash has been an integral part of Pharmidex’s journey, bringing strong leadership, strategic vision and a deep commitment to advancing our capabilities in drug discovery and development. In his new role as COO, he will play a key part in driving operational excellence and supporting the continued growth of the company. This appointment reflects both Ash’s contributions to date and our confidence in his leadership as we continue to expand and evolve. Please join us in congratulating Ash on this well-deserved achievement.

World Asthma Day 🌍

May 5, 2026

Asthma affects over 260 million people worldwide and remains a significant unmet medical need. At Pharmidex , we are proud to support the development of next-generation respiratory therapies through: In vivo respiratory disease models Whole Body Plethysmography (WBP) for functional readouts Integrated PK/PD and bioanalysis Our focus is simple: generate high-quality data that enables confident decision-making and accelerates progress for patients. Because behind every dataset is a patient waiting to breathe easier.

Funding Opportunity for Early-Stage Innovators in Scotland

May 1, 2026

Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment. 🗓️ Deadline: 8th May At Pharmidex , we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development. Our capabilities include: TargetExpression ModeOfActionStudies TargetEngagement HitIdentification ADME and PK profiling If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme. 🔗 https://lnkd.in/eZ6vVjgN